concentration procedure is shown. calculation …antihypertensive therapy for early-stage diabetic...
Post on 22-Jun-2020
3 Views
Preview:
TRANSCRIPT
NMeanS.D.CV(%)Max.Min.
104.1
0.081.944.24.0
Level 1
1051.70.260.5152.051.1
Level 2
10118.70.710.60
120.0117.9
Level 3
Measurement Value (ng/mL)
Within-run Reproducibility
Basic Performance Data (Example : Hitachi 7180)
■ Measurement Range
Bilirubin F
Bilirubin C
Hemoglobin
Chyle
Glucose
Ascorbic acid*
20 mg/dL
20 mg/dL
500 mg/dL
2400 Formazin Turbidity Unit
4000 mg/dL
100 mg/dL
added volume
4.746.15.1
47.84.4
44.84.6
46.15.3
49.44.4
44.7
Without interferent
4.944.74.9
46.14.7
46.34.4
42.44.9
47.84.8
45.2
With interferent
measured value (ng/mL)
Interference
* Ascorbic acid may interfere with the L-FABP assay from around 100 mg/dL depending on the sample.
Assay Procedure
* Spot or pooled urine(No acidified pooled or toluene-preserved urine) ** The difference in absorbance between 570 nm and 800 nm. Calibrator: L-FABP Calibrator(Manufacture's assigned value) Reagent blank: Saline
Sample (urine*) 4 μLmeasurement 1
(absorbance 1**)+ R2 50 μLR1 150 μL37℃
approx. 50 sec37℃
approx. 5 min
measurement 2(absorbance 2**)
ConcentrationCalculation
37℃approx. 4 min
Other package sizes are available upon request
Liver - type Fatty Acid Binding Protein (L-FABP) Reagent
Ready-to-use liquid reagent
Applicable to various automated analyzers
Features
1
2
■ Assessment of Assay Results
1. The assay range is calculated using the L-FABP concentration (μg/gCr) within 1 g of Urine Creatinine, and corrected with the Urine Creatinine value. Conversion Formula: L-FABP (μg/gCr) = L-FABP (ng/mL)/Cr (mg/dL) × 1002. Reference Range: 8.4 μg/gCr and below (Ref: Kamijo A, et al. Diabetes Care 34 (3), 691, 2011)
NORUDIA L-FABP
1.0~200 ng/mL(Hitachi 7180)
L-FABP Buffer Solution 1
Name
NORUDIA L-FABP
Assay Principle Package
2℃ - 10℃1 bottle × 18 mL
1 bottle × 7 mL
Storage
Latex Agglutination TurbidimetryL-FABP Latex Reagent 2
Reagent Kit
This product is compatible with various types of automated analyzer. An example of the assay procedure is shown.
EIA (ng/mL)
Correlation200
150
100
50
0140 18016012010040 60 8020
N = 65 y = 1.07x + 0.28 r = 0.984
NORU
DIA
L-FA
BP (n
g/m
L)
Detection Limit200
175
150
125
100
75
50
25
02.72.4 3.93.0 3.3 3.62.11.81.51.20.90.60.3
Aver
age
abso
rban
ce (m
Abs.
)
Measured value (ng/mL)
Mean±2.6SD(n=10)
0.7ng/mL
Prozone
Mea
sure
d va
lue
(ng/
mL)
350
300
250
200
150
100
50
03000200010000
Theoretical value (ng/mL)Control Level Ⅰ Control Level Ⅱ Control Level Ⅲ
Days (Calibrated only on day 0)
On-board Stability
Mea
sure
d va
lue
(ng/
mL)
140
120
100
80
60
40
20
06 8 10 122 4 14 16 18
Please note the On-board stability may differ depending on the type of analyzer and measured environment. When use of this product please preform accuracy control, and calibrate as necessary.
* Parameters to check for prozone effect are required.
5 concentrations × 1.0 mL
Name
L-FABP CalibratorL-FABP Control
Package
2℃ - 10℃
Storage
2 concentrations × 1.0 mL × 3 vials each
Sold Separately
For the early detectionof kidney injury
For more information contact:
"NORUDIA" is a trademark owned by SEKISUI MEDICAL CO.,LTD. JAPAN, and is registered in Japan and other countries.
Diagnostics Business Unit
1-3, Nihonbashi 2-chome, Chuo-ku, Tokyo 103-0027 JAPANTel: +81-3-3272-0828, Fax: +81-3-3272-0907E-mail: international@sekisui.comWeb: www.sekisuimedical.jp/english LF-103
1808 JBA1000
:p < 0.05 [vs.non-AKI] :p < 0.05 [vs. before surgery]
Urin
e L-
FABP
(μg/
g-Cr
)
800
600
400
200
0 Before After 3h 6h 24h18h 48h
*
*
**
*
*,
*,
*
Tubule
Glomerulus
80
100
20
40
60
0
150
160
120
130
140
110Alb L-FABP Systolic blood pressure
■ Before treatment ■ After 6 months ■ After 12 months
Rate
of c
hang
e (%
)
Systolic blood pressure (mm
Hg)
Glomerular injury
Failure of �ltration function
Albumin, Type IV collagen
Tubular reabsorption dysfunction
Injury/In�ammation ofrenal tubule
NAG
α1-MG, β2-MG
Marker for the early stage detection of kidney injury
What is L-FABP ?■ A fatty acid binding protein found in the renal proximal tubule■ Excreted in the urine due to oxidative stress or renal tubule ischemia before kidney injury■ A useful marker for the early diagnosis of renal disease that involves tubular disorder
1000
100
10
1
Healthy individuals70cases
Stage 164 cases
Stage 230 cases
Stage 327 cases
Stage 419 cases
Diabetic Nephropathy
Urine L-FABP level by disease stage (μg/gCr)
Tsukasa Nakamura,et al.Diabetologia 50(2):490-492,2007
Based on Kamijo-Ikemori A,et al.Diabetes Care 34:691-696,2011
Katsuomi Matsui,et al.Circulation Journal 76:213-220,2012
Process: 85 cardiovascular surgery patients were divided into AKI and non-AKI cohorts based on the AKIN criteria. Urine L-FABP and Serum CRE were measured immediately before and at several after points surgery.
Results: With the conventional AKI diagnosis method which uses serum creatinine as an indicator, AKI symptoms were con�rmed 24 hrs after surgery. However, Urine L-FABP shows a signi�cant increase within the AKI patient cohort immediately after surgery. This indicates that Urine L-FABP is a useful marker for predicting AKI at an early stage.
Acute Kidney Injury (AKI) - Prediction of onset
Seru
m c
reat
inin
e (m
g/dL
)
1.8
1.6
1.4
1.2
1.0
0.8
0.6Before After 3h 6h 24h18h 48h
**
***
*,
Urin
e L-
FABP
(μg/
g-Cr
)
Standard deviation mean value
Healthy Stage 1 p<0.05
Healthy Stage 2 p<0.05
Healthy Stage 3 p<0.05
Healthy Stage 4 p<0.05
AKI patient group (48)non-AKI patient group (37)
Mainly re�ects signs of Renal Dysfunction Re�ects signs of stress on torenal tubule before cytotoxicity
L-FABP
L-FABP
Renal tubuleischemia
Oxidative stress
Re�ects the RESULT
of Kidney Injury
Re�ects the CAUSE
of Kidney Injury
Albumin Free fatty acidLipid peroxides
Reactive oxygen, generated due to peritubular ischemia/reperfusion injury, changes free fatty acids to lipid peroxides which are highly toxic to cells.
L-FABP binds with these lipid peroxides and is excreted outside of cells. Thus, it is thought that L-FABP is "renoprotective", and works to protect the kidneys.
1
2
L-FABP
L-FABP Urinary excretion within the proximal tubule cytoplasm
LysosomeMitochondria
To urine Renal tubule lumen
Tubulointerstitual side
Cytoplasm of proximal tubule
Ischemia-reperfusion injury
ReactiveOxygen
Oxidative Stress
Process: The Urine L-FABP levels of 140 Diabetic nephropathy patients were subdivided based on disease stage. The mean and standard deviation values were calculated and compared to those of healthy individuals.
Results: The Urine L-FABP levels of Diabetic nephropathy patients increased with the progress of disease stage. As it shows a signi�cant increase compared to healthy individuals even from the early stages of nephropathy, it can be inferred that L-FABP has utility in the early diagnosis of Diabetic nephropathy.
Diabetic Nephropathy - Early stage diagnosis
Process: Diabetic nephropathy patients with microalbuminuria were given ARB for 12 months. The Urine Albumin levels, Urine L-FABP levels, and systolic blood pressure were monitored to deternire the effects of medical treatment.
Results: Large decrease of Urine Albumin levels, Unine L-FABP levels, and systolic blood pressures were observed after 6 months and 12 months when compared to the start of treatment. Similar to Urine Albumin, Urine L-FABP is effective for the monitoring and assessment of treatment, such as antihypertensive therapy for early-stage diabetic nephropathy.
Chronic Kidney Disease - Monitoring and assessment of treatment
Excretion of
Urinary L-FABP values re�ect the level of stress given to the kidneys
ConventionalRenal Disease Markers
top related